Art

J-GLOBAL ID：201902253876871048   Reference number：19A2680358

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

進行食道扁平上皮癌難治性または非耐性の患者におけるニボルマブ対化学療法(引力-3):多施設,無作為化,オープンラベル,第3相試験【JST・京大機械翻訳】

Author (18)： Kato Ken (Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan) ,  Cho Byoung Chul (Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea) ,  Takahashi Masanobu (Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan) ,  Okada Morihito (Department of Surgical Oncology, Hiroshima University Hospital, Hiroshima, Japan) ,  Lin Chen-Yuan (Department of Hematology and Oncology, China Medical University Hospital and School of Pharmacy, China Medical University, Taichung City, Taiwan) ,  Chin Keisho (Gastroenterological Chemotherapy Department, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan) ,  Kadowaki Shigenori (Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan) ,  Ahn Myung-Ju (Department of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea) ,  Hamamoto Yasuo (Department of Internal Medicine, Keio Cancer Center, School of Medicine, Keio University, Tokyo, Japan) ,  Doki Yuichiro (Department of Surgery, Osaka University Hospital, Osaka, Japan) ,  Yen Chueh-Chuan (Division of Medical Oncology, Center for Immuno-oncology, Department of Oncology, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, Taiwan) ,  Kubota Yutaro (Department of Oncology, Showa University Hospital, Tokyo, Japan) ,  Kim Sung-Bae (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea) ,  Hsu Chih-Hung (Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan) ,  Holtved Eva (Department of Clinical Oncology, Odense University Hospital, Odense, Denmark) ,  Xynos Ioannis (Oncology Clinical Development, Bristol-Myers Squibb, Princeton, NJ, USA) ,  Kodani Mamoru (Department of Oncology, ONO Pharmaceutical Company, Osaka, Japan) ,  Kitagawa Yuko (Department of Surgery, Keio University School of Medicine, Tokyo, Japan)
Material： Lancet Oncology  (Lancet Oncol)
Volume： 20  Issue： 11  Page： 1506-1517  Publication year： 2019 
JST Material Number： W1266A  ISSN： 1470-2045  Document type： Article
Article type： 原著論文  Country of issue： Netherlands (NLD)  Language： ENGLISH (EN)

Abstract/Point： Chemotherapy for patients with...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=19A2680358&from=J-GLOBAL&jstjournalNo=W1266A") }}

Thesaurus term： interaction ,  *phase 3 study ,  therapy ,  follow-up study ,  Recurrence ,  survival ratio ,  *drug therapy ,  Pneumonia ,  Anemia ,  Republic of Korea ,  Safety ,  tumor ,  toxicity ,  adverse reaction
Semi thesaurus term： 有害事象 ,  全生存率 , 【Automatic Indexing@JST】

JST classification (1)： Treatment for tumors in general  (GE03031L)

Terms in the title (9)： 食道扁平上皮癌 ,  耐性 ,  患者 ,  ニボルマブ ,  化学療法 ,  引力 ,  施設 ,  ラベル ,  第3相試験